IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

Bibliographic Details
Title:	IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia
Authors:	Castillo, Jorge J. ¹, Tam, Constantine S. ², Garcia-Sanz, Ramon ³, Opat, Stephen ⁴, D'Sa, Shirley ⁵, Jurczak, Wojciech ⁶, Lee, Hui-Peng ⁷, Cull, Gavin ⁸, Owen, Roger G. ⁹, Marlton, Paula ¹⁰, Wahlin, Bjorn E. ¹¹, Tedeschi, Alessandra ¹², Siddiqi, Tanya ¹³, Buske, Christian ¹⁴, Leblond, Veronique ¹⁵, Chan, Wai Y. ¹⁶, Schneider, Jingjing ¹⁶, Cohen, Aileen ¹⁶, Dimopoulos, Meletios ¹⁷
Source:	In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S385-S385
Database:	ScienceDirect

More Details
ISSN:	21522650
DOI:	10.1016/S2152-2650(22)01551-8
Published in:	Clinical Lymphoma, Myeloma and Leukemia
Language:	English